Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma

Lung Cancer

Volumn 36, Issue 3, 2002, Pages 257-261

  Potti, Anil ^a   Willardson, James ^a   Forseen, Caralee ^a   Kishor Ganti, Apar ^a   Koch, Michael ^b   Hebert, Brian ^a   Levitt, Ralph ^c   Mehdi, Syed A ^d  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b MeritCare Hospital   (United States)

^c MeritCare Roger Maris Cancer Center   (United States)

^d Fargo VA Medical Center   (United States)

Author keywords

Clinical course; Extensive stage small cell carcinoma; HER 2 neu overexpression; Outcome; Symptoms

Indexed keywords

PARAFFIN;

AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; DYSPNEA; FEMALE; GENE OVEREXPRESSION; HOARSENESS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; THORAX PAIN; THORAX RADIOGRAPHY; TUMOR BIOPSY; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0036252954     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00488-3     Document Type: Article

References (45)

1. Cancer of the lung
2. Cancer statistics, 1996
3. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma
4. Cancer statistics, 1994
5. Lung cancer
6. Long-term survival in small-cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - An analysis of 1,714 consecutive patients
7. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute
8. Basic science of HER-2/neu: A review
9. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
10. Expression of neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung
11. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract
12. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue
13. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma
14. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed Mullerian tumors). Clinicopathologic study of 82 cases
15. HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival
16. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer
17. C-erbB-2 oncoprotein over-expression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease
18. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemias
19. Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
20. Effective HER-2/neu diagnosis in breast cancer by a combination of immunochemistry and FISH
21. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
22. Nonparametric estimation from incomplete observations
23. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer
24. Outcome of patients with small cell lung cancer: Effect of changes in staging procedures and imaging technology on prognostic factors over 14 years
25. Prognostic factors for patients with small cell lung carcinoma
26. Chimiothérapie des cancers bronchiques à petites cellules. Impotence dune réponse complete (1,280 patients)
27. Autocrine growth factors and cancer
28. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
29. Expression of epidermal growth factor receptor (EGF-R) in human lung tumors
30. Aberrant expression of p53 and the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development
31. Phase I studies of anti-epidermal growth factor receptor (EGFR) Chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors
32. Insulin like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell line in vitro
33. Overview of genetic and molecular events in the pathogenesis of lung cancer
34. Prognostic value of c-erbB-2 in human lung adenocarcinoma and squamous cell carcinoma
35. Epidermal growth factor and c-erbB-2 in human lung cancer
36. Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study
37. C-erbB-2 expression in small cell lung cancer is associated with poor response
38. Analysis of serum erbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer
39. Over-expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
40. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group
41. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
42. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
43. Overexpression of both p185c-erbB-2/neu and p170mdr-1 renders breast cancer cells highly resistant to Taxol via MDR-1 independent mechanisms
44. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via MDR-1 independent mechanisms
45. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations